{{위키데이터 속성 추적}}
{{Infobox drug
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 596899008
| INN = 덱삼페타민
| type = <!-- empty -->
| image = D-amphetamine.svg
| width = 200
| alt = 
| caption =

<!-- Clinical data -->
| pronounce = {{IPAc-en|ˌ|d|ɛ|k|s|t|r|əʊ|æ|m|ˈ|f|ɛ|t|ə|m|iː|n}}
| tradename = Dexedrine, Dextrostat, Xelstrym, Zenzedi, others
| Drugs.com = {{drugs.com|monograph|dextroamphetamine}}
| MedlinePlus = a605027
| licence_EU =
| DailyMedID = dextroamphetamine
| licence_US = dextroamphetamine
| pregnancy_AU = B3
| pregnancy_AU_comment = 
| pregnancy_category= 
| dependency_liability = Moderate<ref name="Vitiello2008">{{저널 인용| vauthors = Vitiello B | title = Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function | journal = Child and Adolescent Psychiatric Clinics of North America | volume = 17 | issue = 2 | pages = 459–74, xi | date = April 2008 | pmid = 18295156 | pmc = 2408826 | doi = 10.1016/j.chc.2007.11.010 }}</ref><ref name="GrahamGrahamBanaschewski2010">{{저널 인용| vauthors = Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Döpfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E | display-authors = 6 | title = European guidelines on managing adverse effects of medication for ADHD | journal = European Child & Adolescent Psychiatry | volume = 20 | issue = 1 | pages = 17–37 | date = January 2011 | pmid = 21042924 | pmc = 3012210 | doi = 10.1007/s00787-010-0140-6 | eissn = 1435-165X }}</ref> - high<ref name="KociancicReedFindling2004">{{저널 인용| vauthors = Kociancic T, Reed MD, Findling RL | title = Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children | journal = Expert Opinion on Drug Safety | volume = 3 | issue = 2 | pages = 93–100 | date = March 2004 | pmid = 15006715 | doi = 10.1517/14740338.3.2.93 | s2cid = 31114829 | eissn = 1744-764X }}</ref><ref name="ClemowWalker2014">{{저널 인용| vauthors = Clemow DB, Walker DJ | title = The potential for misuse and abuse of medications in ADHD: a review | journal = Postgraduate Medicine | volume = 126 | issue = 5 | pages = 64–81 | date = September 2014 | pmid = 25295651 | doi = 10.3810/pgm.2014.09.2801 | s2cid = 207580823 | eissn = 1941-9260 }}</ref>
| addiction_liability = Moderate<ref name="Vitiello2008"/><ref name="GrahamGrahamBanaschewski2010"/> - high<ref name="KociancicReedFindling2004"/><ref name="ClemowWalker2014"/>
| routes_of_administration = [[Oral administration|By mouth]], [[Transdermal patch|transdermal]]
| class = 
| ATC_prefix = N06
| ATC_suffix = BA02
| ATC_supplemental =

<!-- Legal status -->
| legal_AU = S8
| legal_AU_comment =<ref>{{웹 인용| title=Therapeutic Goods (Poisons Standard—February 2023) Instrument 2022 | website=Australian Government Federal Register of Legislation | url=https://www.legislation.gov.au/Series/F2022L01257 | access-date=9 January 2023}}</ref><ref>{{웹 인용| vauthors = Fuller K | title=ADHD Stimulant Prescribing Regulations & Authorities in Australia & New Zealand | website=AADPA | date=20 February 2022 | url=https://aadpa.com.au/adhd-stimulant-prescribing-regulations-in-australia-new-zealand/ | access-date=9 January 2023}}</ref>
| legal_BR = A3
| legal_BR_comment =<ref>{{웹 인용|author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-03-31 |title=RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |url-status=live |archive-url=https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |archive-date=2023-08-03 |access-date=2023-08-16 |publisher=[[Diário Oficial da União]] |language=pt-BR |publication-date=2023-04-04}}</ref>
| legal_CA = Schedule I
| legal_CA_comment = 
| legal_DE = Anlage III
| legal_DE_comment = 
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment = 
| legal_UK = Class B
| legal_UK_comment = 
| legal_US = Schedule II
| legal_US_comment =<ref name="Dexedrine FDA label">{{웹 인용| title=Dexedrine spansule- dextroamphetamine sulfate capsule, extended release | website=DailyMed | date=10 January 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc717b9b-22ea-4c60-a1d4-ee38a40bce78 | access-date=28 March 2022}}</ref><ref name="Xelstrym FDA label">{{웹 인용| title=Xelstrym- dextroamphetamine patch, extended release | website=DailyMed | date=6 January 2023 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0862f02a-72a8-41cc-8845-57cf4974bb6f | access-date=21 January 2023}}</ref>
| legal_EU = Rx-only
| legal_EU_comment =<ref>{{웹 인용|url=https://www.ema.europa.eu/documents/psusa/dexamfetamine-list-nationally-authorised-medicinal-products-psusa/00000986/202109_en.pdf |title=List of nationally authorised medicinal products : Active substance(s): dexamfetamine : Procedure No. PSUSA/00000986/202109|website=Ema.europa.eu|access-date=5 June 2022}}</ref>
| legal_UN = P II<!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment = 
| legal_status = <!-- For countries not listed above -->

<!-- Pharmacokinetic data -->
| bioavailability = Oral: 75–100%<ref>{{백과사전 인용| title=Dextromphetamine | url=http://www.drugbank.ca/drugs/DB01576#pharmacology | work=DrugBank | access-date=5 November 2013 | section=Pharmacology }}</ref>
| protein_bound = 15–40%
| metabolism = [[CYP2D6]], [[Dopamine β-hydroxylase|DBH]],<ref name="DBH ref">{{서적 인용| title=Foye's Principles of Medicinal Chemistry | year=2013 | publisher=Wolters Kluwer Health/Lippincott Williams & Wilkins | location=Philadelphia | isbn=978-1609133450 | page=648 |vauthors=Lemke TL, Williams DA, Roche VF, Zito W |edition=7th | quote=Alternatively, direct oxidation of amphetamine by DA β-hydroxylase can afford norephedrine.}}</ref> [[Flavin-containing monooxygenase|FMO3]]
| metabolites = 
| onset = {{abbr|IR|Immediate release}} dosing: 0.5–1.5&nbsp;hours<ref>{{서적 인용|title = Primary Care Pediatrics|url = https://books.google.com/books?id=o43u_qWT4asC|publisher = Lippincott Williams & Wilkins|date = 1 January 2001|isbn = 9780781720083| vauthors = Green-Hernandez C, Singleton JK, Aronzon DZ |page = 243}}|quote = Table 21.2 Medications for ADHD ... D-amphetamine ... Onset: 30 min.</ref><ref>{{웹 인용|title = Dexedrine, ProCentra(dextroamphetamine) dosing, indications, interactions, adverse effects, and more|url = http://reference.medscape.com/drug/dexedrine-procentra-dextroamphetamine-342998#10|website = reference.medscape.com|access-date = 4 October 2015|quote = Onset of action: 1–1.5 hr}}</ref><br />{{abbr|XR|Extended release}} dosing: 1.5–2&nbsp;hours<ref name="Millichap: onset, peak, and duration">{{서적 인용| vauthors = Millichap JG | editor = Millichap JG | title = Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD | year = 2010 | publisher = Springer | location = New York, USA | isbn = 9781441913968 | page = 112 | edition = 2nd | chapter = Chapter 9: Medications for ADHD | quote = <br />Table 9.2 Dextroamphetamine formulations of stimulant medication<br />Dexedrine [Peak:2–3&nbsp;h] [Duration:5–6&nbsp;h]&nbsp;...<br />Adderall [Peak:2–3&nbsp;h] [Duration:5–7&nbsp;h]<br />Dexedrine spansules [Peak:7–8&nbsp;h] [Duration:12&nbsp;h]&nbsp;...<br />Adderall XR [Peak:7–8&nbsp;h] [Duration:12&nbsp;h]<br />Vyvanse [Peak:3–4&nbsp;h] [Duration:12&nbsp;h]}}</ref><ref name="XR onset-duration">{{저널 인용| vauthors = Brams M, Mao AR, Doyle RL | title = Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder | journal = Postgrad. Med. | volume = 120 | issue = 3 | pages = 69–88 | date = September 2008 | pmid = 18824827 | doi = 10.3810/pgm.2008.09.1909 | s2cid = 31791162 | quote = Onset of efficacy was earliest for d-MPH-ER at 0.5 hours, followed by d, l-MPH-LA at 1 to 2 hours, MCD at 1.5 hours, d, l-MPH-OR at 1 to 2 hours, MAS-XR at 1.5 to 2 hours, MTS at 2 hours, and LDX at approximately 2 hours.&nbsp;... MAS-XR, and LDX have a long duration of action at 12 hours postdose}}</ref>
| elimination_half-life = 9–11&nbsp;hours<ref name="Adderall IR">{{웹 인용| title=Adderall- dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablet | website=DailyMed | date=27 February 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db81 | access-date=21 January 2023}}</ref><br />[[pH]]-dependent: 7–34&nbsp;hours
| duration_of_action = {{abbr|IR|Immediate release}} dosing: 3–6&nbsp;hours<ref name="Millichap: onset, peak, and duration" /><ref name="Narcolepsy guide">{{저널 인용| vauthors = Mignot EJ | title = A practical guide to the therapy of narcolepsy and hypersomnia syndromes | journal = Neurotherapeutics | volume = 9 | issue = 4 | pages = 739–752 | date = October 2012 | pmid = 23065655 | pmc = 3480574 | doi = 10.1007/s13311-012-0150-9 }}</ref><br />{{abbr|XR|Extended release}} dosing: 8–12&nbsp;hours<ref name="Stahl's Essential Psychopharmacology - dextroamphetamine">{{서적 인용| vauthors=Stahl SM | title=Prescriber's Guide: Stahl's Essential Psychopharmacology | date=March 2017 | publisher=Cambridge University Press | location=Cambridge, United Kingdom | isbn=9781108228749 | pages=39–44 | edition=6th | chapter-url=https://books.google.com/books?id=9hssDwAAQBAJ&pg=PA39 | chapter=Amphetamine (D) | access-date=8 August 2017 }}</ref><ref name="Millichap: onset, peak, and duration" /><ref name="Narcolepsy guide"/>
| excretion = [[Kidney]] (45%);<ref>{{웹 인용|title=dextrostat (dextroamphetamine sulfate) tablet [Shire US Inc.]|publisher=Shire US Inc.|website=DailyMed|url=http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=1645|date=August 2006|access-date=8 November 2013|location=Wayne, PA}}</ref> urinary pH-dependent

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 51-64-9
| CAS_supplemental = 
| PubChem = 5826
| IUPHAR_ligand = 2147
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01576
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5621
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = TZ47U051FI
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03740
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4469
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 612
| NIAID_ChemDB = 
| PDB_ligand = 
| synonyms = d-Amphetamine, (S)-Amphetamine, S(+)-Amphetamine

<!-- Chemical and physical data -->
| IUPAC_name = (2''S'')-1-phenylpropan-2-amine
| C=9 | H=13 | N=1
| SMILES = C[C@@H](Cc1ccccc1)N
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1
| StdInChI_comment =
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KWTSXDURSIMDCE-QMMMGPOBSA-N
| density = 0.913
| density_notes = 
| melting_point =
| melting_high = 
| melting_notes =
| boiling_point = 201.5
| boiling_notes =
| solubility = 20
| sol_units = 
| specific_rotation = 
}}

'''덱스트로암페타민'''({{llang|en|dextroamphetamine}})은 [[중추신경계]] [[각성제]]이자 [[암페타민]]의 [[거울상 이성질체]]{{Refnest|group="주"|거울상 이성질체는 서로에 대해 거울상인 분자이다. 거울상 이성질체는 구조적으로 동일하지만 방향이 반대이다.}} 로 [[주의력 결핍 과잉 행동 장애]](ADHD) 및 [[기면증]] 치료에 처방된다.<ref name="Dexedrine FDA label">{{웹 인용| title=Dexedrine spansule- dextroamphetamine sulfate capsule, extended release | website=DailyMed | date=10 January 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc717b9b-22ea-4c60-a1d4-ee38a40bce78 | access-date=28 March 2022}}</ref><ref name="Amph Uses">{{저널 인용|vauthors=Heal DJ, Smith SL, Gosden J, Nutt DJ | title = Amphetamine, past and present – a pharmacological and clinical perspective | journal = J. Psychopharmacol. | volume = 27 | issue = 6 | pages = 479–496 |date=June 2013 | pmid = 23539642 | pmc = 3666194 | doi = 10.1177/0269881113482532}}</ref> 또한 덱스트로암페타민은 운동 능력과 인지 강화제로도 사용되며 기분 전환을 위해 [[최음제]]와 도취제로도 사용된다.

== 같이 보기 ==
* [[거울상 이성질체]]
* [[암페타민]]

== 주해 ==
{{각주|group="주"}}

== 각주 ==
{{각주}}

[[분류:암페타민]]
[[분류:식욕억제제]]
[[분류:최음제]]
[[분류:심장혈관계통에 작용하는 약]]
[[분류:신경계통에 작용하는 약]]
[[분류:거울상 순수 약물]]
[[분류:운동 보조제]]
[[분류:도취제]]
[[분류:흥분성 아미노산 재흡수 저해제]]
[[분류:누트로픽]]
[[분류:노르에피네프린-도파민 방출제]]
[[분류:펜에틸아민]]
[[분류:자극제]]
[[분류:TAAR1 작용제]]
[[분류:주의력 결핍 과잉 행동 장애 관리]]
[[분류:VMAT 억제제]]
[[분류:세계 반도핑 기구 금지 약물]]
[[분류:경기력 향상 약물]]